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26 The molecular mechanisms underlying the ERα nuclear/cytoplasmic pool that modulates 
27 pituitary cell proliferation have been widely described, but it is still not clear how ERα is 
28 targeted to the plasma membrane. The aim of this study was to analyse ERα palmitoylation 
29 and the plasma membrane ERα (mERα) pool, and their participation in E2-triggered 
30 membrane-initiated signalling in normal and pituitary tumour cell growth. Cell cultures were 
31 prepared from anterior pituitaries of female Wistar rats and tumour GH3 cells, and treated 
32 with 10nM of estradiol (E2). The basal expression of ERα was higher in tumour GH3 than in 
33 normal pituitary cells. Full-length palmitoylated ERα was observed in normal and pituitary 
34 tumour cells, demonstrating that E2 stimulation increased both, ERα in plasma membrane 
35 and ERα and caveolin-1 interaction after short-term-treatment. In addition, the Dhhc7 and 
36 Dhhc21 palmitoylases were negatively regulated after sustained stimulation of E2 for 3h. 
37 Although the uptake of BrdU into the nucleus in normal pituitary cells was not modified by 
38 E2, a significant increase in the GH3 tumoral cell, as well as ERK1/2 activation, with this 
39 effect being mimicked by PPT, a selective antagonist of ERα. These proliferative effects were 
40 blocked by ICI 182780 and the global inhibitor of palmitoylation. These findings indicate that 
41 ERα palmitoylation modulated the mERα pool and consequently the ERK1/2 pathway, 
42 thereby contributing to pituitary tumour cell proliferation. These results suggest that the 
43 plasma membrane ERα pool might be related to the proliferative behaviour of  prolactinoma, 
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50 Oestrogens act as important regulators of cell proliferation, cell survival, and 
51 differentiation in a variety of organ systems and tissues and have been implicated in the 
52 aetiology of a variety of malignant cancers and benign tumours, such as pituitary adenomas 
53 (Spady, et al. 1999). Most of the effects of oestrogen are mediated through its two receptors: 
54 oestrogen receptor alpha (ERα) and beta (ERβ) (Mitchner, et al. 1998). ERα expression has 
55 been detected in both normal and tumour cells secreting PRL and gonadotropin (Friend, et al. 
56 1994), and at higher levels in macroadenomas than in microadenomas, and in non-invasive 
57 tumours than in invasive ones (Meitzen, et al. 2013). It has been demonstrated that an 
58 oestrogen receptor antagonist inhibited pituitary tumour growth in a prolactinoma 
59 experimental model (Heaney, et al. 2002), thereby making ERα a potential target for the 
60 treatment of high ERα-expressing pituitary adenomas (Gao, et al. 2017).
61 In addition to the classic nuclear genomic action, oestrogens have been found to 
62 induce rapid effects within minutes of administration, which are mediated through a 
63 subpopulation of oestrogen receptors associated with the plasma membrane, a process usually 
64 termed “membrane-initiated steroid signalling” (MISS), “nongenomic” or “extranuclear” 
65 effects (Ueda and Karas 2013; Watson, et al. 2005). Related to this, we previously 
66 demonstrated that 17β-estradiol (E2) and FGF2 exerted a cooperative effect on lactotroph 
67 proliferation, principally by signalling initiated at the plasma membrane and mediated by the 
68 MEK/ERK1/2 pathway (Sosa Ldel, et al. 2013). 
69 The molecular mechanisms underlying the ERα nuclear/cytoplasmic pool  modulating 
70 adenohypophyseal cell activity have been widely described. Although, it is still not clear how 
71 ERα is targeted to the plasma membrane in normal and pituitary tumour cells, it has been 
72 reported that one of the requirements for ER to be located at the plasma membrane is the 
73 presence of a hydrophobic segment as part of the receptor structure (Marino, et al. 2006; 
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74 Morrill, et al. 2015). A post-translational modification of ERα has been previously described, 
75 which includes the addition of a palmitate molecule (S-acylation, commonly called 
76 palmitoylation) in cysteine residues of the ligand binding region of the gonadal steroid 
77 receptors (Acconcia, et al. 2005; Pedram, et al. 2007), by the palmitoyl-acyltransferases 
78 (PATs) DHHC7 and DHHC21 (Pedram, et al. 2012). Adding lipid residues increases 
79 hydrophobicity, promoting steroid receptor translocation to the caveolae regions of the 
80 plasma membrane (Peffer, et al. 2014; Razandi, et al. 2002), with the different isoforms of 
81 caveolin (caveolin-1, caveolin-2) being involved in this mechanism (Le Lay and Kurzchalia 
82 2005; Totta, et al. 2015). ERα localisation in caveolae regions has been described in ovarian, 
83 prostate and breast tumour cells, suggesting an interaction between caveolin-1 and steroid 
84 receptors, which contributes to mERα localisation as well as to the activation of extra-nuclear 
85 estradiol signalling (Acconcia, et al. 2003; Park, et al. 2009; Pedram, et al. 2002). However, 
86 the functional role of palmitoylation in normal and pituitary tumour cell proliferation and 
87 signalling has not yet been explored. 
88 The results reported in the literature are related only to total ERα expression, thus it is 
89 interesting to evaluate of mERα expression in pituitary tumours. In the present study, we 
90 speculated that the mERα pool modulates cell proliferation in pituitary tumours. Thus, we 
91 tested the hypothesis that the increase of mERα mediated by palmitoylation triggers ERK1/2 
92 phosphorylation and consequently pituitary tumour cell growth.
93
94  MATERIALS AND METHODS 
95 Cell cultures 
96 A pool of three-month-old female Wistar rats, (n=12) , bred and housed at the Animal 
97 Research Facility of National University of Cordoba, was assigned to each culture taken at 
98 random cycle stages. The protocol for the dissociation of pituitary cells has been described 
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99 previously (De Paul, et al. 2011). The normal pituitary primary culture includes different type 
100 of cells, with the lactotroph (54.1%) and somatotroph (21.8%) being the two principal cell 
101 populations (data not shown). After 3 days culture, the cells were maintained in DMEM 
102 without phenol red and serum for 24h before applying the treatments. The experiments were 
103 approved by the Institutional Animal Care Committee of the School of Medicine, University 
104 National of Cordoba.
105 The rat GH3 lactosomatotroph cell line is derived from rat prolacting-secreting 
106 pituitary tumors which synthesize both prolactin and growth hormone, and has been used as a 
107 prolactinoma model (Boockfor, et al. 1985; Chao, et al. 2014). The cells were cultured in 
108 Ham’s F-12 medium, supplemented with 2.5% foetal bovine serum and 15% horse serum 
109 (Gibco, NY, USA). The cell cultures with a confluence of 80% were maintained in DMEM 
110 without phenol red and serum for 24h and then submitted to different experimental protocols 
111 GH3 and primary adenohypophysis cells, were stimulated for 30min with E2 (10nM),  
112 a selective ERα agonist: 4,4’,4’’-(4-propyl-[1H]-pyrazole-1,3,5-tryl) trisphenol (10 nM, PPT) 
113 or EGF (10ng/mL). For some experiments, the cells were pre-incubated with the global 
114 inhibitor of palmitoylation, 2-bromohexadecanoic acid (2BP; 10μM) or ER  pure antagonist: 
115 ICI 182780, for 30 min.
116 Determination of palmitoylated proteins by acyl-biotin exchange (ABE) assay 
117 The palmitoylated proteins were determined by the ABE assay according to Wan 
118 (Wan, et al. 2007) with modifications. The cells were extracted in cold lysis buffer (1.25% 
119 Igepal CA-630, 1mM EDTA, and protease and phosphatase inhibitors), and the proteins were 
120 concentrated by precipitation in chloroform-methanol and suspended in the SB buffer (50mM 
121 Tris-HCl, pH7.4, 5mM EDTA, 4% SDS) with N-methylmaleimide (NEM-10mM). Next, 
122 1mM NEM was added to the LB buffer (50mM Tris-HCl, pH7.4, 5mM EDTA, 150mM 
123 NaCl), which was incubated overnight at 4°C. The samples were divided into two equal 
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124 portions H and Tris; with the H samples being diluted in HB buffer (1M hydroxylamine, 
125 150mM NaCl, 0.2%Triton and 1mM HPDP-Biotin) and the Tris samples being diluted with 
126 the same buffer without hydroxylamine. Purification of the biotinylated proteins was 
127 completed by diluting with LB buffer containing streptavidin-agarose beads. Finally, the 
128 samples were re-suspended in 35μl LB containing 0.1% SDS, 0.2% TritonX-100 and 1% β-
129 mercaptoethanol and heated to 95°C. The proteins were analysed by western blot using 
130 primary antibody anti-ERα (1/200; Santa Cruz-Biotechnology, CA). 
131 The GH3 cell line was transfected with the plasmid encoding SX8-Cherry as a control 
132 of palmitoylated proteins. The expression plasmid (1μg) and the transfection reagent PEI 
133 (2μl, Sigma Aldrich, USA) were added for 2h and then the GH3 cells were maintained in 
134 Ham’s F-12 an additional 24h.
135 Analysis of cell-surface proteins by biotinylation
136 The cell cultures were washed with PBS buffer and the cell-surface labelled proteins 
137 were purified using a cell surface protein isolation kit (Pierce, Rockford, IL). The proteins 
138 from the supernatant and pellet fractions were analysed by western blot using the specific 
139 primary antibodies (Santa Cruz Biotechnology, CA): anti-phosphorylated ERα (1/200), anti-
140 β-actin (1/1000), anti-FGFR (1/200) and anti-EGFR (1/400). 
141 Immunoprecipitation 
142 The protein extract was subjected to immunoprecipitation using anti-ERα (5μg/mL). 
143 The immune complexes were adsorbed and precipitated using protein G-Sepharose beads 
144 (Sigma Aldrich-St. Louis, MO, USA), washed and denatured by boiling for 5min in sample 
145 buffer. The samples were analysed by western blot using anti-ERα (1/200) and anti-caveolin-
146 1 (1/1000; Cell Signaling Technology, Beverly, MA, USA). 
147 Preparation of cell lysates for western blotting analysis 
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148 The samples were lysed in cold lysis buffer and the total homogenate (50µg) was 
149 separated using 12% polyacrylamide gel. The proteins on nitrocellulose membrane were 
150 blocked with 5% non-fat dried milk and 0.1% Tween20 at RT and incubated overnight with 
151 primary antibodies 1/700 anti-diphosphorylated ERK1/2 (Sigma-Aldrich, St. Louis, USA) 
152 and 1/1000 anti-total ERK1 (Santa Cruz Biotechnology, Inc). The blots were incubated with 
153 peroxidase-conjugated anti-rabbit (1/5000) or anti-mouse (1/2500 Jackson Immunoresearch 
154 Labs Inc, PA, USA) secondary antibodies and then revealed with ECL detection reagents 
155 (Inmun-Star HRP-Substrate Kits, Bio-Rad, CA, USA). Finally, the emitted light was captured 
156 by the C-DiGit Chemiluminescence Scanner (LI-COR Biosciences), and signals were 
157 quantified with ImageJ software.
158 Gene expression analysis by qPCR 
159 qPCR analysis of cDNA was performed on an ABI Prism 7500 detection system 
160 (Applied Biosystem, Foster City, CA) using Power SYBR Green PCR Master Mix (Thermo 
161 Fisher Scientific, MA) and the upper and lower gene-specific primer sequences used were: 
162 DHHC-7 (NM_133394.1) 5’-GAGGATGGACCACCACTGTC-3’ and 5’-
163 CATGATAGCCAGCTCATGC-3’; DHHC-21 (XM_006238345.1) 5’-
164 GAGGATGGACCACCACTGTC-3’ and 5’-TCATGATAGCCAGCTCATGC-3’; DHHC-11 
165 (NM_001039342.2) 5’-AACAACTTGACTTGGCCTACG-3’ and 5’-
166 GGCGAAAGAGTAGACAGCA-3’; and β-actin (NM_031144) 5’-
167 CCCACACTGTGCCCATCTA-3’ and 5’-CGGAACCGCTCATTGCC-3’. 
168 Immunogold electron microscopy 
169 The subcellular localisation of the ERα and caveolin-1 in normal and GH3 cells was 
170 examined by ultrastructural immunocytochemical techniques applying previously 
171 standardized protocols (Petiti, et al. 2015). Thin sections in the grids were incubated with 
172 anti-ERα (1/200) followed by anti-caveolin-1 (1/500) antibodies overnight at 4°C. Then the 
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173 sections were incubated with anti-rabbit or anti-mouse secondary antibodies conjugated to 
174 15nm and 5nm colloidal gold particles (1/30, Electron Microscopy Science, USA) and 
175 examined in a Zeiss LEO 906-E transmission EM (TEM) (Zeiss, Oberkochen, Germany).
176 Immunofluorescence
177 For mERα staining, non-permeabilised live cells were incubated with ERα/Alexa 
178 fluor 594 for 15 min at 4°C prior to fixation. The ERα/Alexa fluor 594 complex was prepared 
179 by mixing an adequate dilution of ERα primary antibody and Alexa fluor 594 secondary 
180 antibody for 30 min at 4°C before incubation with the cells. Images were obtained using a 
181 Confocal Laser Scanning Microscope FluoView FV 300 (Olympus; Tokyo, Japan) and 
182 processed using FV10-ASW 1.6 Viewer software. 
183 Correlative Light and Electron Microscopy (CLEM) 
184 CLEM was carried out on ultrathin cryosections by applying the Tokuyasu technique 
185 as described by Oorschot (Oorschot, et al. 2014). The cryosections were transferred on 
186 formvar-coated 100µm mesh nickel grids and incubated with anti-ERα antibody 1/50 in 1% 
187 BSA-PBS, followed by incubation with anti-rabbit Alexa-Fluor594 (1/300, Invitrogen, 
188 California, USA) and DAPI (Sigma-Aldrich, St. Louis, USA) for 1h at 37°C.
189 For fluorescence light microscopy (FLM), grids layered with a 200nm coat of 2% 
190 methylcellulose were mounted with 50% glycerol. For TEM observation, grids were 
191 unmounted, washed in milli-Q water and incubated in 0.4% uranyl acetate/1.8% 
192 methylcellulose. Fluorescence images were obtained using a confocal laser scanning 
193 microscope FluoView FV 1200 (Olympus, Tokyo, Japan) and, EM images using a Zeiss LEO 
194 906-E TEM. The analysis was carried out with ImageJ software.
195 Immunocytochemical detection of bromo-deoxyuridine uptake 
196 Cells at the DNA synthesising stage were identified by immunocytochemical 
197 detection of BrdU. After 30min of E2 stimulation, BrdU (100nM) was added for an 
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198 additional 24h. The cells attached to the coverslips were fixed in 4% formaldehyde in PBS 
199 for 2h at room temperature and BrdU incorporation detection was performed as described by 
200 Ferraris (Ferraris, et al. 2014). A total of 1000 cells were examined using a systematic 
201 process on each glass slide to establish the proportion of positive BrdU in the total cells. 
202 Data analysis 
203
204 A statistical analysis was carried out on three replicates measured from three 
205 independent cell cultures, with ANOVA-Tukey using InfoStat software (Grupo InfoStat, 
206 Facultad de Ciencias Agropecuarias, UNC). The results are given as the means ±SEM, and 
207 the significance levels were set at p< 0.05.
208 RESULTS 
209 ERa expression in normal and pituitary tumour cells
210 First, we analysed the expression of total ERα in normal and pituitary tumour cells. 
211 The expression of ERα was higher in tumour GH3 than in normal pituitary cells and this did 
212 not change with the 30 min E2 treatment (Fig.1A). Next, to determine whether ERα was 
213 palmitoylated in normal adenohypophysis and in GH3 pituitary tumour cells, the ABE assay 
214 was carried out followed by western blot. ERα full-length expression was observed as bands 
215 at around 66 kDa, and this protein was detected as palmitoylated in line H of ABE, in normal 
216 adenohypophysis cells (Fig. 1B-top) and in the GH3 cell line (Fig. 1B-bottom). Furthermore, 
217 an additional ERα-immunoreactive band around 50kDa was detected in the palmitoylated 
218 proteins line in GH3 cells, possibly corresponding to the splicing variant of ERα. The SX8-
219 Cher transfection in GH3 tumour cells showed a 70 kDa band in line H of ABE, confirming 
220 the presence of this palmitoylated protein (Fig. 1B-bottom).
221 E2 regulates Dhhc7 and Dhhc21 palmitoylase expression
222 Considering that the PATs are key to regulating the subcellular localisation of 
223 different ERα pools, Dhhc7 and Dhhc21 were evaluated by qPCR. As shown in Figure 1 C-
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224 D, the Dhhc7 and Dhhc21 mRNA basal levels were higher in tumour than in normal cells. 
225 Then, we evaluated whether E2 was able to regulate the mRNA expression levels of these 
226 enzymes, with a significant decrease in Dhhc7 (Fig. 1-E) and Dhhc21 (Fig. 1-F) mRNA 
227 levels being observed in normal and GH3 cells stimulated with E2 for 3h compared to 
228 control. However, this reduction was transient, as Dhhc7 and Dhhc21 mRNA levels returned 
229 to baseline values after 6 or 9h of E2 treatment. The expression of Dhhc11 mRNA levels, 
230 used as a negative control, did not vary after E2 treatment either cell type (Fig.1-G). 
231 Membrane ERα expression is regulated by palmitoylation
232 To explore whether palmitoylation could promote changes in mERα expression, 
233 pituitary cells were pre-treated with 2BP, the global inhibitor of palmitoylation, and then 
234 stimulated with E2 for 30min. In unstimulated and nonpermeabilized pituitary cells, 
235 endogenous ERα specific immunostaining was observed at the plasma membrane in some 
236 normal pituitary and pituitary tumour cells. However, E2 treatment for 30 min increased ERα 
237 expression at the plasma membrane, which was more frequently observed in tumour cells, 
238 and was reverted when the cells were pre-treated with 2BP (Fig. 2A-C). We visualised the 
239 expression of ERα by CLEM (Fig.2B and D), which enabled simultaneous observation of a 
240 given subcellular structure. In normal (Fig.2B) and tumour GH3 (Fig.2D) cells, the ERα was 
241 localised at the plasma membrane when the cells were treated with E2 for 30 min. 
242 The changes in mERα expression in pituitary cells were analysed by cell surface 
243 biotinylation. As shown in Figure 2, western blot analysis revealed the presence of ERα in the 
244 pellet fraction (containing the cell surface biotinylated proteins) and in the supernatant 
245 fraction (with the intracellular unbiotinylated proteins). In the pellet fraction, under baseline 
246 conditions, lower ERα protein expression was observed in both normal (E) and tumour (F) 
247 cells, whereas E2 treatment for 30 min significantly increased mERα expression, which was 
248 completely reversed by the 2BP pre-treatment. 
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249 E2 induces ERα and caveolin-1 association
250 As interaction between ERα and caveolin-1 has benn described in different tissues 
251 (Peffer et al. 2014; Wang, et al. 2011), we evaluated whether E2 could promote any 
252 interaction in pituitary cells by using a co-immunoprecipitation assay. As shown in Figure 3, 
253 in normal (A) and GH3 (C) unstimulated cells, a basal interaction was observed between both 
254 proteins, which was significantly increased by E2 treatment. Interestingly, 2BP treatment was 
255 able to reverse the E2-induced ERα/caveolin-1 interaction, revealing similar expression levels 
256 as the controls. 
257 In addition, we analysed the fine localisation of ERα with caveolin-1 by means of 
258 TEM immunogold labelling in normal (B) and tumour GH3 (C) cells. As shown in Figures 
259 4B and C, the immunoreactivity for ERα (15nm gold particle) was distributed in the 
260 cytoplasm and occasionally in the plasma membrane in normal and tumour control cells, 
261 whereas ERα localisation was frequently observed the plasma membrane, with caveolin-1 
262 (5nm gold particles) being close to each other in E2-treated cells. 
263 The involvement of palmitoylation and mERα in cell proliferation 
264 To analyse the contribution of mERα to cell proliferation, we determined the BrdU 
265 uptake into the nucleus of normal and pituitary tumour cells incubated with a palmitoylation 
266 inhibitor. The percentage of control normal BrdU positive cells was 2.6%, with no changes 
267 observed after the different treatments (Fig. 4 A-B). However, in non-stimulated GH3 cells, 
268 the proliferation was around 30%, showing a significant increase after E2 stimulation that 
269 was mimicked for PPT respect to control. The E2 effect was blocked partially by ICI 182780 
270 and the global inhibitor of palmitoylation, 2BP (Fig. 4 C-D).
271 Considering previous results from our laboratory concerning the involvement of the 
272 MEK/ERK1/2 and PI3K/AKT pathways in pituitary tumour cell proliferation (Petiti, et al. 
273 2010; Petiti et al. 2015), we determined the phosphorylation of ERK1/2 and AKT in pituitary 
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274 tumour cells. Figure 4E shows the significant increase in phosphorylated ERK1/2 after E2 
275 and PPT treatments  observed for 30 min, which was blocked when the cells were pre-
276 incubated with ICI 182780 or 2BP, suggesting that ERα palmitoylation may be required to 
277 activate these kinases. The expression of phosphorylated AKT increased after E2 or PPT 
278 treatments for 30 min, while pre-incubation with ICI 182780 or 2BP did not revert this 
279 activation, suggesting that AKT may contribute to the pituitary tumour proliferation induced 
280 by E2 in a mERα-independent manner.
281 Additionally, we tested if the effect of the inhibitor of palmitoylation could affect the 
282 cell response to different growth stimulatory factors. With this aim, we analyzed the 
283 proliferation and activation of ERK1/2 in GH3 cells stimulated with the epidermal growth 
284 factor (EGF) for 30 min, in the presence or absence of the pre-incubation with 2BP. As 
285 shown in figure 4, the EGF treatment significantly increased the uptake of BrdU and ERK1/2 
286 phosphorylation (Fig. 4 F-G), effects that were not reverted when the cells were pre-treated 
287 with 2BP, suggesting that the cell response to palmitoyation inhibitor is ER specific.
288 The above results indicate that the plasma membrane ERα localisation mediated by 




293 This study, found that the subpopulation of ERα localised in the plasma membrane 
294 induced pituitary tumour proliferation by the mREα/cavelin1/ERK1/2 pathway. The E2 
295 stimuli significantly increased mERα expression, ERα interaction with caveolin-1, ERK1/2 
296 phosphorylation, and finally led to pituitary tumour proliferation, which were partially 
297 reversed by the PAT inhibitor.
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298  We previously identified the presence of ERα in the plasma membrane in normal 
299 pituitary cells (Gutierrez, et al. 2008), and  it has also been demonstrated that E2 stimulates 
300 the translocation of endogenous ERα and the activation of the PKCα/ERK1/2 pathway 
301 (Gutierrez, et al. 2012; Watson, et al. 2012; Zarate, et al. 2012), without any effect on cell 
302 proliferation (Sosa Ldel et al. 2013). Considering that lactotroph cells represent the main 
303 phenotype in adult female rat pituitaries that express ERα, and that GH3 cells have been 
304 employed as a prolactinoma model, we compare the ERα expression in GH3 vs. normal 
305 pituitary cells. The analysis of mERα expression by western blot and immunofluorescence, 
306 reveled an increased level of this receptor in tumour cells compared to normal pituitary cells. 
307 The involvement of mERα in the rapid pro-apoptotic action of oestradiol in normal pituitary 
308 cells has been previously demonstrated (Zarate et al. 2012). In contrast, in pituitary tumour 
309 GH3B6/F10 cells, high levels of mERα mediated rapid signalling responses to oestrogens, 
310 which culminated in functional changes such as prolactin release, cell proliferation, 
311 apoptosis, and changes in cell shape (Jeng, et al. 2009; Jeng and Watson 2011). However, 
312 these studies in both normal and pituitary tumour cell, did not reveal the contribution of 
313 palmitoylation to ERα translocation to the plasma membrane. In the present investigation, we 
314 detected palmitoylated ERα in normal and GH3 pituitary tumour cells for the first time, and 
315 demonstrated that E2 stimulated ERα expression in the plasma membrane, which was 
316 reverted by the palmitoylation inhibitor. Thus, palmitoylation (a reversible posttranscriptional 
317 modification) should be considered to be more than just a simple membrane association of 
318 soluble proteins. In fact, the palmitoylation status of several proteins has also been linked to 
319 their activation and the regulation of the traffic and function of both the nuclear/cytoplasmic 
320 and the membrane receptor pool (Fukata and Fukata 2010).
321 In addition to full-length mER, we detected an ERα palmitoylated variant at around 
322 50kDa in the membrane fraction of pituitary tumour cells. In agreement with this, other 
Page 13 of 34 Accepted Manuscript published as JOE-18-0418.R1. Accepted for publication: 31-Oct-2018
Copyright © 2018 Society for Endocrinology Downloaded from Bioscientifica.com at 11/21/2018 06:25:15PM
via free access
14
323 authors have reported that, as well as full-length 66-kDa ERα, truncated forms of this 
324 receptor were present in various organs, produced by alternate ER mRNA splicing or specific 
325 post-translational processing, often outside the nucleus. In agreement, a 46-kDa truncated 
326 variant has been shown to be preferentially palmitoylated and enriched in the cell membranes 
327 of endothelial, osteoblast, and breast cancer cells (Denger, et al. 2001; Li, et al. 2003; 
328 Marquez and Pietras 2001), and palmitoylation inhibitors were able to block ER-46 
329 membrane localisation (Acconcia et al. 2005). Moreover, variants of lower molecular weights 
330 (∼39 kDa and ∼22 kDa) were detected in the membrane fraction of anterior pituitary cells 
331 (Zarate et al. 2012) and breast cancer cells, suggesting that these ERα variants may be 
332 considered as a target of palmitoylation and result in their localisation in the plasma 
333 membrane (Li et al. 2003; Wang, et al. 2006). 
334 Palmitoyl-acyltransferase isoform expression and localisation is tissue-specific (Ohno, 
335 et al. 2006), with at least a dozen of the 23 human DHHC genes having been implicated in 
336 tumour growth (Yeste-Velasco, et al. 2015). DHHC7 and DHHC21 are the proteins 
337 responsible for the palmitoylation of the sex steroid oestrogen, progesterone and androgen 
338 receptors. DHHC-7 and -21 knockdown studies have shown that PATs are required for 
339 endogenous ER palmitoylation, membrane trafficking, and rapid signal transduction in cancer 
340 cells (Pedram et al. 2012). In the present study, we observed greater Dhhc7 and Dhhc21 
341 mRNA expression in tumour cells than in normal pituitary cells, which may be associated 
342 with the proliferative behaviour of GH3 cells. It has been reported that the Dhhc21 gene is 
343 significantly overexpressed in human breast cancer compared with normal breast epithelium. 
344 It is possible that alterations in the steroid receptor PAT abundance or function contribute to 
345 increased ER at the plasma membrane in some situations (Pedram et al. 2012), thereby 
346 making the DHHC-7 and -21 proteins attractive novel targets to selectively inhibit membrane 
347 sex steroid receptor localisation and function in pituitary tumours. 
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348 Although s-acylation is known to be a major regulator of localisation of cellular 
349 protein and pathways, there is still little information about how the dynamics of this process 
350 is regulated. It has also been reported that palmitoylation regulation may occur via a 
351 regulatory mechanism occurring at the mRNA level of the DHHC enzymes (Chai, et al. 
352 2013). In this study, E2 treatment for 3h reduced both Dhhc7 and Dhhc21 mRNA expression, 
353 whereas at  30 min the plasma-membrane ERα pool and the interaction ERα/caveolin were 
354 increased. The current knowledge of estrogen molecular action includes the ability of the E2–
355 ER complex both to induce gene transcription (Smith and O'Malley 2004) and to evoke the 
356 membrane starting activation of specific rapid phosphorylation cascades (ERK/MAPK) 
357 (Yang, et al. 2004). Both these processes are integrated and influence the cellular response to 
358 estrogen, thus highlighting the ER regulation at genomic and nongenomic levels. The fast 
359 action/membrane of E2 (30 min) was not in line with that observed after sustained 
360 stimulation of E2 for 3 h, which downregulated the mRNA levels of Dhhc7 and Dhhc21, 
361 probably as a compensatory mechanism to regulate the ERα pool at the plasma membrane. 
362 These results are in agreement those of an investigation that, demonstrated that E2 
363 stimulation for 1 to 4h decreased by 60% the [3H]-palmitate incorporated into ERα in HeLa 
364 cells, suggesting that ERα palmitoylation is negatively modulated by E2 (Acconcia et al. 
365 2005). 
366 The relationship between ERα and caveolin appears to be important for determining 
367 E2 effects on different cell types, with it having been demonstrated that caveolin-1 is an 
368 essential  for joining ERα to the cell membrane, and that this process is facilitated by prior 
369 ER palmitoylation (Pedram et al. 2007). Our results revealed that the ERα/caveolin-1 
370 interaction increased after E2 stimulus in normal as well as in GH3 pituitary tumour cells. 
371 Concurring with our data, an ERα/caveolin-1 interaction was demonstrated in enriched mERα 
372 GH3/B6/F10 pituitary tumour cells (Watson et al. 2012). In addition, it has been reported 
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373 that, as oestradiol is highly concentrated in isolated caveolae, it readily engages ERα bound 
374 to caveolin-1, which serves as a scaffold for membrane-localised signalling molecules (Peffer 
375 et al. 2014). Therefore, caveolin may be a fundamental scaffolding protein whose activation 
376 maximises membrane hormone effects and leads to specific biological consequences. This 
377 idea is supported by caveolin knockdown rats as they, showed a reduction in membrane ERα 
378 functions, thereby suggesting that trafficking of ERα to the plasma membrane is mediated by 
379 caveolin (Christensen and Micevych 2012). It has also been demonstated that caveolin-1 
380 protein down-regulation leads to ERα signalling deregulation in mammary epithelia (Wang et 
381 al. 2011). We observed that the ERα/caveolin-1 association was palmitoylation-dependent, as 
382 indicated by the decrease in this association after palmitoylation inhibition. A non-
383 palmitoylable ERα-Cys477Ala mutant was unable to localise at the plasma membrane, 
384 interact with caveolin-1, or generate E2-induced rapid membrane-starting signal pathways to 
385 regulate cell proliferation (Acconcia et al. 2005). Moreover, it has been demonstrated that 
386 ERα rapid de-palmitoylation and decoupling the ERα action mechanisms impair the 
387 activation of the ERK/MAPK and PI3K/AKT signal transduction pathways (Levin 2005; 
388 Totta, et al. 2004). These reports are in  agreement with our results, where it was observed 
389 that pre-incubation with 2BP in GH3 tumoral cells decreased the ERα and caveolin-1 
390 interaction, as well as ERK1/2 phosphorylation, suggesting that palmitoylation is necessary 
391 for a mediated E2 effect.
392 Several members of the MAP kinase signalling pathway, including Src, Shc, and 
393 ERKs, are clustered in caveolae-specialized membrane invaginations that are enriched in the 
394 caveolin-1 scaffolding protein and compartmentalise signal transduction (Okamoto, et al. 
395 1998). ERα activation may trigger cell proliferation mediated by ERK (Jeng et al. 2009; 
396 Watson et al. 2012; Watson, et al. 2010), with the MEK/ERK1/2 pathway being involved in 
397 the pathogenesis of several types of tumours including pituitary adenomas (Ebbesen, et al. 
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398 2016; Vlotides, et al. 2008). It has been reported that the inhibition of ERK1/2 signalling 
399 reduced cell viability in rat tumour cells after exposure to a general antagonist of ER (Gao et 
400 al. 2017). Here, we observed that the estrogen antagonist and the palmitoylation inhibitor 
401 prevented the activation of ERK1/2 and resulted in a decrease in ERα expression levels in the 
402 plasma membrane as well as in cell pituitary proliferation, indicating that rapid E2-induced 
403 signals require ER localisation at the plasma membrane. Pedram et al reported that 
404 knockdown of DHHC7 or 21 significantly impaired the ability of E2 to stimulate ERK in 
405 breast cancer cells (Pedram et al. 2012). In addition, the expression of ERα without a 
406 palmitoylated site interfered with endogenous ER function and inhibited E2-induced ERK 
407 activation, cyclin D1 production, cdk4 activity, and G1/S progression, suggesting that the 
408 inhibition of mERα expression and its association with the modulation of ERK activity could 
409 be put forward as an important therapeutic intervention in breast cancer (Razandi, et al. 
410 2003).
411 It is generally accepted that oestrogens act as potent mitogens through ERα, exerting a 
412 sustained, dose-dependent trophic stimulus on anterior pituitary proliferation (Nolan and 
413 Levy 2009). In our study, in primary pituitary cells with a basal proliferation of 2.6%, E2 
414 treatment was unable to modify this mitotic rate. In contrast, in pituitary tumour cells, which 
415 exhibited a high basal proliferative activity, E2 stimulation triggered an increase in BrdU 
416 uptake with a significant contribution of mERα. Furthermore, palmitoylation inhibition 
417 induced a significant decrease in cell proliferation, which was consistent with previous 
418 reports showing that mERα contributes, together with the nuclear ERα pool, to the induction 
419 of tumour cell proliferation (Razandi et al. 2003). In addition, significantly increased ERα 
420 localization in the plasma membrane has been associated with aggressive breast cancer 
421 behaviour or resistance to endocrine therapy (Fan, et al. 2007; Yang et al. 2004).
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422 Moreover, these result indicated that oestrogens were able to trigger a proliferative 
423 response in the pituitary tumour cell, associated with high levels of ERα and the activation of 
424 ERK1/2 signalling (Jeng et al. 2009; Watson, et al. 2008). In breast cancer cells, E2-ERα-
425 induced cell transition through G1 to the S phase of the cell cycle, which significantly 
426 blocked by 2BP or by inhibitors of MEK, suggesting that membrane localisation of 
427 palmitoylated ERα leads to a signal transduction that contributes to cell cycle progression 
428 (Pedram et al. 2007). Additionally, the ERK/MAPK and PI3K/AKT pathways, activated by 
429 the E2–ERα complex, cooperatively promote the G1/S transition (Acconcia et al. 2005; 
430 Marino, et al. 2002). In our study, we observed that the palmitoylation inhibitor induced a 
431 partial reversion in the tumour proliferation by E2 in a pERK1/2 dependent and pAKT 
432 independent manner.
433  The differences in the proliferation effect observed between normal and pituitary 
434 tumour cells under E2 treatment may be explained by the high ERα expression in tumour 
435 cells compared to normal cells, as well as by the undetectable subtype REβ expression in 
436 GH3 pituitary tumour cells as was previously reported in our laboratory. In addition, we 
437 determined the specific role of ERβ in the E2 proliferative effect in normal, hyperplastic and 
438 pituitary tumour cells, with this hormone being able to increase pituitary cell proliferation 
439 only in cells with a high ERα/β ratio, showing that ERβ exerts an inhibitory role on the 
440 mitogenic activity of pituitary cells (Perez, et al. 2015). The reason that different cellular 
441 phenotypes can respond to the same hormone in a different manner may be due to the diverse 
442 expression patterns of ERα and ERβ (McDonnell and Norris 2002). 
443 In summary, our results showed that E2 modulated ERα palmitoylation, enhancing the 
444 mERα pool and consequently activating the ERK pathway, thereby contributing to pituitary 
445 tumour cell proliferation. These findings suggest that mERα could be related to the 
446 proliferative behaviour of prolactinoma and be a possible marker of pituitary tomour growth. 
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3 A- Basal expression of total REa in normal and pituitary tumour cells and after E2 treatment 
4 for 30 min. 
5 B- Protein extracts from pituitary cells were tested for palmitoylated ERα following the ABE 
6 assay. Biotinylated proteins were purified, separated by SDS-PAGE and stained with anti-
7 REα antibody. ERα palmytoilation is prominent in protein extracts that were treated with 
8 hydroxylamine (H). In addition, in GH3 transfected SX8-Cher tumour cells, palmitoylated 
9 SX8 was used as a control of palmitoylated protein. The Input in A and B was 10% of total 
10 protein extract and Tris: pull down without H. 
11 Relative mRNA expression levels of Dhhc7 (C) and Dhhc21 (D) in normal pituitary and GH3 
12 tumour cells. Dhhc7 (E), Dhhc21 (F)  and Dhhc11 (G) mRNA expression levels after 
13 treatment with E2 (10nM) at 3, 6 and 9 h. A significant decrease in the Dhhc7 and Dhhc21 
14 mRNA levels was observed in normal and GH3 cells stimulated with E2 for 3h compared to 
15 control. Expression levels were calculated by quantitative real-time PCR analysis. The β-
16 actin gene was used as the internal reference gene and the ΔΔCT method was used for 
17 relative quantification and expressed as fold over control: * p<0.05 Dhhc7 vs C and ^ p<0.05 
18 Dhhc21 vs C.
19 Figure 2
20 Cell surface immunostaining of ERα in non-permiabilised normal (A) and tumour GH3 (B) 
21 cell cultures treated with E2 (10nM) for 30 min with or without pre-treatment of 2BP. 
22 Microphotograph represent the merging of Light transmitted  and immunofluorescence field. 
23 CLEM of normal pituitary (C) and GH3 tumour (D) rat cell cultures were treated with E2. [1] 
24 Immunofluorescence labelling for ERα, [2] TEM images for the whole section and [3] CLEM 
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2
25 overlay of TEM on the corresponding FLM image. Arrows indicate ERα at plasma 
26 membrane. Bar: 10µm
27 Biotinylation of cell-surface biotinylated proteins in normal pituitary and tumour GH3 rat 
28 cells. Surface membrane proteins were biotinylated in normal control (E) and tumour GH3 
29 (F) pituitary cells or in cells treated with E2 (10 nM) for 30 min with or without 2BP pre-
30 incubation. Whole cell lysates were subjected to avidin pull-down using streptavidin-agarose 
31 beads, and the recovered cell-surface biotinylated proteins (pellet) and intracellular 
32 unbiotinylated proteins (supernatant) were analysed by western blot and stained with anti-
33 REα antibody. In the pellet fraction, ERα expression showed an increase after E2 treatment 
34 but a decrease after pre-treatment with 2BP. The ERα expression did not change after 
35 treatment in the supernatant. The expression of the FGF and EGF receptors and β-actin 
36 confirmed equivalent total protein loading. Images correspond to a representative experiment 
37 from a total of three with similar results. Values are expressed as mean ± SEM. * p<0.05 E2 
38 vs C and ^ p<0.05 E2-2BP vs E2. 
39 Figure 3 
40 Association between ERα and caveolin 1. Normal pituitary (A) and tumour GH3 (C) rat cell 
41 cultures were treated with E2 (10nM) for 30 min with or without pre-treatment of 2BP. The 
42 total cell extracts were used for immunoprecipitation (IP) using anti-ERα and the 
43 immunoprecipitates were then probed with anti-cav-1. *P<0.01 E2 vs. C and ^ p<0.05 E2-
44 2BP vs E2. In total anterior pituitary cell culture lysates, both antibodies recognised the 
45 antigens (input). 
46 Electron micrographs of normal pituitary (B) and tumour GH3 (D) with double immune-
47 labelling of ERα (15 nm gold particle) and cav-1 (5nm gold particle). The black arrows 
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48 indicate the ERα-cav-1 adhered to the plasma membrane and the white arrows indicate the 
49 cytosolic ERα. g=granule; Bar: 100nm
50 Figure 4 
51 Representative micrographs of immunohistochemical staining for BrdU (red) and  
52 quantitative analysis in normal (A-B)  and tumour GH3 (C-D) cell cultures. The cells were 
53 treated with E2 (10nM) or PPT (10 nM) for 30 min with or without pre-treatment with 2BP 
54 or ICI 182780 (I, 100 nM). BrdU was added for an additional 24h and the data represent the 
55 proportion of positive BrdU cells in the total cells. Significant differences were found in GH3 
56 cell proliferation: *p<0.01 E2 or PPT vs. C and ^ p<0.05 I+ E2 vs E2. #p<0.05 E2 or PPT 
57 vs.E2 or PPT and ~p<0.05 2BP-I+E2 vs.E2.  Bar: 100µm. (E) Western blotting of ERK1/2 
58 and Akt in total extract from tumour pituitaries treated with E2 (10nM) or PPT (10 nM) for 
59 30 min with or without pre-treatment of 2BP or ICI 182780 (I, 100 nM). The amount of 
60 protein levels was normalised by comparison with total ERK1/2 and AKT expression A 
61 representative panel of three independent experiments is shown. (F-G) Quantitative analysis 
62 of BrdU staining and western blotting of ERK1/2 in total extract from cells treated with EGF 
63 (10ng/mL) for 30min with or without pre-treatment with 2BP (10uM). Significant differences 
64 were found in GH3 cell proliferation: *p<0.01 EGF vs. C, while that cell proliferation and 
65 ERK1/2 phosphorylation did not change with 2BP treatment.
66
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Figure 1: A- Basal expression of total REα in normal and pituitary tumour cells and after E2 treatment for 30 
min. B- Protein extracts from pituitary cells were tested for palmitoylated ERα following the ABE assay. 
Biotinylated proteins were purified, separated by SDS-PAGE and stained with anti-REα antibody. ERα 
palmytoilation is prominent in protein extracts that were treated with hydroxylamine (H). In addition, in GH3 
transfected SX8-Cher tumour cells, palmitoylated SX8 was used as a control of palmitoylated protein. The 
Input in A and B was 10% of total protein extract and Tris: pull down without H. Relative mRNA expression 
levels of Dhhc7 (C) and Dhhc21 (D) in normal pituitary and GH3 tumour cells. Dhhc7 (E), Dhhc21 (F)  and 
Dhhc11 (G) mRNA expression levels after treatment with E2 (10nM) at 3, 6 and 9 h. A significant decrease 
in the Dhhc7 and Dhhc21 mRNA levels was observed in normal and GH3 cells stimulated with E2 for 3h 
compared to control. Expression levels were calculated by quantitative real-time PCR analysis. The β-actin 
gene was used as the internal reference gene and the ΔΔCT method was used for relative quantification and 
expressed as fold over control: * p<0.05 Dhhc7 vs C and ^ p<0.05 Dhhc21 vs C. 
108x95mm (200 x 200 DPI) 
Page 30 of 34Accepted Manuscript published as JOE-18-0418.R1. Accepted for publication: 31-Oct-2018
Copyright © 2018 Society for Endocrinology Downloaded from Bioscientifica.com at 11/21/2018 06:25:15PM
via free access
 
Figure 2: Cell surface immunostaining of ERα in non-permiabilised normal (A) and tumour GH3 (B) cell 
cultures treated with E2 (10nM) for 30 min with or without pre-treatment of 2BP. Microphotograph represent 
the merging of Light transmitted  and immunofluorescence field. 
CLEM of normal pituitary (C) and GH3 tumour (D) rat cell cultures were treated with E2. [1] 
Immunofluorescence labelling for ERα, [2] TEM images for the whole section and [3] CLEM overlay of TEM 
on the corresponding FLM image. Arrows indicate ERα at plasma membrane. Bar: 10µm 
Biotinylation of cell-surface biotinylated proteins in normal pituitary and tumour GH3 rat cells. Surface 
membrane proteins were biotinylated in normal control (E) and tumour GH3 (F) pituitary cells or in cells 
treated with E2 (10 nM) for 30 min with or without 2BP pre-incubation. Whole cell lysates were subjected to 
avidin pull-down using streptavidin-agarose beads, and the recovered cell-surface biotinylated proteins 
(pellet) and intracellular unbiotinylated proteins (supernatant) were analysed by western blot and stained 
with anti-REα antibody. In the pellet fraction, ERα expression showed an increase after E2 treatment but a 
decrease after pre-treatment with 2BP. The ERα expression did not change after treatment in the 
supernatant. The expression of the FGF and EGF receptors and β-actin confirmed equivalent total protein 
loading. Images correspond to a representative experiment from a total of three with similar results. Values 
are expressed as mean ± SEM. * p<0.05 E2 vs C and ^ p<0.05 E2-2BP vs E2. 
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Figure 3: Association between ERα and caveolin 1. Normal pituitary (A) and tumour GH3 (C) rat cell cultures 
were treated with E2 (10nM) for 30 min with or without pre-treatment of 2BP. The total cell extracts were 
used for immunoprecipitation (IP) using anti-ERα and the immunoprecipitates were then probed with anti-
cav-1. *P<0.01 E2 vs. C and ^ p<0.05 E2-2BP vs E2. In total anterior pituitary cell culture lysates, both 
antibodies recognised the antigens (input). Electron micrographs of normal pituitary (B) and tumour GH3 
(D) with double immune-labelling of ERα (15 nm gold particle) and cav-1 (5nm gold particle). The black 
arrows indicate the ERα-cav-1 adhered to the plasma membrane and the white arrows indicate the cytosolic 
ERα. g=granule 
194x299mm (200 x 200 DPI) 
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Figure 4: Representative micrographs of immunohistochemical staining for BrdU (red) and  quantitative 
analysis in normal (A-B)  and tumour GH3 (C-D) cell cultures. The cells were treated with E2 (10nM) or PPT 
(10 nM) for 30 min with or without pre-treatment with 2BP or ICI 182780 (I, 100 nM). BrdU was added for 
an additional 24h and the data represent the proportion of positive BrdU cells in the total cells. Significant 
differences were found in GH3 cell proliferation: *p<0.01 E2 or PPT vs. C and ^ p<0.05 I+ E2 vs E2. 
#p<0.05 E2 or PPT vs.E2 or PPT and ~p<0.05 2BP-I+E2 vs.E2.  Bar: 100µm. (E) Western blotting of 
ERK1/2 and Akt in total extract from tumour pituitaries treated with E2 (10nM) or PPT (10 nM) for 30 min 
with or without pre-treatment of 2BP or ICI 182780 (I, 100 nM). The amount of protein levels was 
normalised by comparison with total ERK1/2 and AKT expression A representative panel of three 
independent experiments is shown. (F-G) Quantitative analysis of BrdU staining and western blotting of 
ERK1/2 in total extract from cells treated with EGF (10ng/mL) for 30min with or without pre-treatment with 
2BP (10uM). Significant differences were found in GH3 cell proliferation: *p<0.01 EGF vs. C, while that cell 
proliferation and ERK1/2 phosphorylation did not change with 2BP treatment. 
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